PRKDC and cancer: Concordantly, combination of DNA-PK inhibitor, radiotherapy and avelumab in syngeneic mice with p53-mutant cancer cells demonstrated a superior benefit and offers a new approach to combination radio-immunotherapy of cancer [172].